fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Prednisolone acetate

1 general benefit · 1 not a benefit

Ratio-Prednisolone · DIN 00700401 · 1% · Oph suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Ratio-Prednisolone · DIN 00700401 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-04-20 · brand TEVA-PREDNISOLONE · ATC S01BA04 PREDNISOLONE · form Suspension · route Ophthalmic · ingredients PREDNISOLONE ACETATE 1 % · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ratio-Prednisolone: Formulary list price $1.94 per unit (the source does not state the unit; exact figure $1.9400). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00700401)

Source record
DIN 00700401: Ratio-Prednisolone Raw flags: sec3=Y Item: 520800017; group id 600; item number 1560; lccId None; manufacturer id RPH Source form: Oph Susp; strength: 1% Recorded listing: General benefit Source prices (unrounded): $1.9400; ministry $1.9400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00700401 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7042
Interchangeable products
Pred Forte · DIN 00301175 · not recorded
Shortage status: resolved shortage (ended February 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00700401
Shortage record checked October 6, 2026

Pred Forte · DIN 00301175 · 1% · Oph suspension

Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Pred Forte · DIN 00301175 Manufacturer: Allergan Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-09-25 · brand PRED FORTE · ATC S01BA04 PREDNISOLONE · form Suspension · route Ophthalmic · ingredients PREDNISOLONE ACETATE 1 %/W/V · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pred Forte: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00301175)

Source record
DIN 00301175: Pred Forte Raw flags: notABenefit=Y, sec3=Y Item: 520800017; group id 600; item number 1560; lccId None; manufacturer id ALL Source form: Oph Susp; strength: 1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00301175 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1937
Interchangeable products
Ratio-Prednisolone · DIN 00700401 · $1.9400
Shortage status: resolved shortage (ended August 24, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00301175
Shortage record checked October 6, 2026

Other products in the same Health Canada class (S01B, S01BA): coverage varies; not interchangeable

  • Dexamethasone (Maxidex): general benefit
  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Ketorolac tromethamine (Acular): general benefit
  • Bromfenac (Prolensa): not a benefit

Prednisolone sodium phosphate

1 general benefit · 1 not a benefit

PMS-Prednisolone · DIN 02245532 · 6.7 mg/5 mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Prednisolone · DIN 02245532 Manufacturer: Pharmascience Inc.; listing date 2004-07-20 Health Canada: Marketed since 2002-03-19 · brand PMS-PREDNISOLONE · ATC H02AB06 PREDNISOLONE · form Solution · route Oral · ingredients PREDNISOLONE (PREDNISOLONE SODIUM PHOSPHATE) 5 MG/5ML · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Prednisolone: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1259). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245532)

Source record
DIN 02245532: PMS-Prednisolone Raw flags: sec3=Y Item: 680400071; group id 718; item number 1774; lccId None; manufacturer id PMS Source form: O/L; strength: 6.7mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1259; ministry $0.1259 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245532 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69619
Interchangeable products
Pediapred Oral Liquid · DIN 02230619 · not recorded
Shortage status: resolved shortage (ended December 22, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245532
Shortage record checked October 6, 2026

Pediapred Oral Liquid · DIN 02230619 · 6.7 mg/5 mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.Discontinued July 22, 2024 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-07-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Pediapred Oral Liquid · DIN 02230619 Manufacturer: Sanofi Aventis Pharma; listing date 2003-01-30 Health Canada: Cancelled post market since 2024-07-22 · brand PEDIAPRED · ATC H02AB06 PREDNISOLONE · form Solution · route Oral · ingredients PREDNISOLONE (PREDNISOLONE SODIUM PHOSPHATE) 5 MG/5ML · company Sanofi-aventis canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pediapred Oral Liquid: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02230619)

Source record
DIN 02230619: Pediapred Oral Liquid Raw flags: notABenefit=Y, sec3=Y Item: 680400071; group id 718; item number 1774; lccId None; manufacturer id SAV Source form: O/L; strength: 6.7mg/5mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02230619 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49795
Interchangeable products
PMS-Prednisolone · DIN 02245532 · $0.1259
Shortage status: discontinued (December 18, 2023, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230619
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 22, 2024 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (S01B, S01BA): coverage varies; not interchangeable

  • Dexamethasone (Maxidex): general benefit
  • Fluorometholone (Fml): general benefit
  • Fluorometholone (Flarex): general benefit
  • Ketorolac tromethamine (Acular): general benefit
  • Bromfenac (Prolensa): not a benefit
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE 52:08 Anti-Inflammatory Agents

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

BROMFENAC

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.07% w/v · Oph Sol (With Preservative)

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PRED FORTE® (prednisolone acetate) is indicated for: • the treatment of steroid‐responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics No overall differences in safety or effectiveness have been observed in elderly patients https://pdf.hres.ca/dpd_pm/00074796.PDF PM date: FEB 28, 2024 Source product: PRED FORTE; DIN 00301175; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS Management of conditions known to be responsive to prednisone or prednisolone where anti-inflammatory action or immunosuppression or adrenocortical supplementation and replacement is required. For most indications, glucocorticoid administration provides symptomatic relief, but has no effect on the underlying disease processes. Use of these medications does not eliminate the need for other therapies that may be required. 1.1 Pediatrics pms-PREDNISOLONE oral solution is appropriate for pediatric usage and for those patients with difficulty swallowing solid oral dosage forms. https://pdf.hres.ca/dpd_pm/00075127.PDF PM date: MAR 28, 2024 Source product: PMS-PREDNISOLONE; DIN 02245532; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Pediapred Oral Liquid · DIN 02230619 Shortage status: discontinued (2023-12-18, reported by SANOFI-AVENTIS CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230619

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Pred Forte, Pediapred Oral Liquid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026